Lentiviral Packaging and Transduction

Package your lentiviral constructs into high titer, ready-to-transduce VSV-G lentiviral particles.

• Obtain high-titer lentiviral particles for tranduction into almost any mammalian cell
• Get validated packaging reagents for use in your lab
• Use a complete packaging service that delivers functionally titered virus

• Description
• How It Works
• Applications
• Resources
• FAQs

• Cellecta offers Ready-to-Use Packaging Plasmids to produce and LentiFuge viral concentration reagent to produce packaged VSV-g pseudotyped lentiviral particles.

  Alternatively, Cellecta can provide you with your lentiviral constructs in ready-to-transduce, pre-packaged, functionally titered lentiviral particles.

  

• Cellecta's packaging service offers a wide range of packaging yields--from 1x10^6 to 1x10^9 transduction units (TU). Viral packaging preparations are functionally titered based on transduction and counting of fluorescent or antibiotic HEK293 cells. We do not use p24 antibiotic or PCR-based estimates of viral titers unless no fluorescent or antibiotic markers are available. These indirect measurements are often very inaccurate because they do not differentiate functional viral particles from the general presence of viral proteins or RNA.

  

• Lentiviral particle preparations can be directly added to cells in culture. The lentiviral particles fuse with the cell membranes and the lentiviral RNA enters the cell, is reverse-transcribed, and integrated into the cell’s DNA.

  

• Brochures and Presentations

  • Ready-to-Use Lentiviral Packaging Mix
  • LentiFuge™ Viral Concentration Reagent
  • LentiPrep™ Reagent Set

  Application and Tech Notes

  • Lentiviral Vector System

  Citations and Publication

  • SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms (2021)
  • CRISPR/Cas-based modeling of NF2 loss in meningioma cells (2021)
  • A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy (2021)
  • A universal dual mechanism immunotherapy for the treatment of influenza virus infections (2020)
  • ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition (2020)
  • View All Publications

• FAQs

For a sampling of peer-reviewed publications and citations of Cellecta products and services, please visit and search for your product or application of interest on this page.

Products